Skip to main content

Table 1 Baseline characteristics of subjects with type 2 diabetes mellitus and control subjects (n = 106)

From: Sleep-wake cycle irregularities in type 2 diabetics

  Control subjects (n = 32) T2DM subjects (n = 74) p value
Gender, male/female 19/13 37/37 0.4041
Age, years 62 ± 1 (39-83) 66 ± 1 (36-84) 0.5349
Job type
(non/employee/individual proprietor/homemaker/others)
5/14/1/11/1 17/25/1/27/4  
Body mass index, kg/m2 22.7 ± 0.7 (13.9-30.8) 24.7 ± 0.5 (17.8-34.5) 0.0153
Blood glucose, mg/dL 94 ± 3 (53-113) 128 ± 74 (52-252) <0.001
Glycoalbumin, % 14.9 ± 1.0 (12.9-16.0) 19.8 ± 0.6 (12.5-33.3) 0.0243
HbA1c (NGSP), % 5.9 ± 0.1 (5.4-6.3) 7.0 ± 0.1 (5.6-14.4) 0.0001
Systolic blood pressure, mmHg 138 ± 23 (98-174) 137 ± 2 (101-182) 0.9149
Diastolic blood pressure, mmHg 81 ± 2 (65-97) 80 ± 1 (49-105) 0.7800
Triglyceride, mg/dL 175 ± 41 (44-1231) 138 ± 10 (34-471) 0.8158
High-density lipoprotein cholesterol, mg/dL 62 ± 23 (31-121) 53 ± 2 (17-103) 0.0079
Low-density lipoprotein cholesterol, mg/dL 117 ± 5 (80-196) 112 ± 4 (64-208) 0.3333
Uric acid, mg/dL 5.5 ± 0.2 (2.8-7.8) 5.5 ± 0.2 (2.7-9.4) 0.9827
Creatinine, mg/dL 0.70 ± 0.02 (0.46-1.15) 0.86 ± 0.05 (0.44-2.83) 0.0798
Diabetic neuropathy - n = 15  
Diabetic retinopathy (NDR/SDR/PDR) - n = 56/6/12  
Diabetic nephropathy (stage I/II/III/IV) - n = 57/9/3/5  
Drugs for diabetes (medication/insulin) - n = 57/17  
Hypertension (under medications) n = 18 (n = 11) n = 60 (n = 46) 0.0151
Dyslipidemia (under medications) n = 21 (n = 13) n = 48 (n = 34) 0.8253
Insomnia, under medications n = 6 n = 11 0.7736
  1. Data are mean ± SEM or n (range). Significant level was set at p value <0.05 (bold type). T2DM: type 2 diabetes mellitus, NDR: non-diabetic retinopathy, SDR: simple diabetic retinopathy, PDR: proliferative diabetic retinopathy.